trending Market Intelligence /marketintelligence/en/news-insights/trending/bfgiecxoipglimovy57vjg2 content esgSubNav
In This List

Astellas Pharma fiscal Q1 profit climbs 35.5% YOY


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Astellas Pharma fiscal Q1 profit climbs 35.5% YOY

Tokyo-based Astellas Pharma Inc. said its core profit for the first quarter ended June 30 grew 35.5% year over year to ¥70.35 billion.

Basic core EPS was ¥35.70, compared with ¥25.14 per share in the first quarter of fiscal 2017.

Meanwhile, core operating profit for the April-June period totaled ¥84.04 billion, a rise of 29.0% from ¥65.12 billion a year earlier.

Sales rose 2% year over year to ¥329.08 billion from ¥322.57 billion.

Profit attributable to owners of the company for the first fiscal quarter was ¥54.56 billion, or ¥27.65 per share, up from ¥42.47 billion, or ¥20.54 in the year-ago period.

Research and development expenses for the quarter reached ¥52.13 billion, down from ¥56.48 billion the prior year.